Insights
Interviews, press coverage and essays on pharmaceutical innovation, leadership, and building sustainable businesses across borders.
CPHI Frankfurt 2025
CPHI Frankfurt · Nov 2025
RIKO is built on seven years of operational intelligence across 50+ FDA and EU-GMP certified manufacturing partners in 55 countries, reaching 94% predictive accuracy on nitrosamine risk patterns and cutting supplier qualification cycles by 85%.
Read the announcementAlso in: Indian Pharma Post · SMEStreet · Digital Health News · MediaBrief
On why the PLI scheme alone is not enough, and the three structural pillars India still needs: demand assurance for manufacturers, shared GMP testing infrastructure in bulk drug parks, and faster regulatory alignment with the EU and MENA.
Read the featureOn DCGI bridging-data timelines, the runway left for Indian injectable pipelines, and what happens to the domestic reference price if a Chinese oral drug lands between Rs 500 and Rs 800 a month.
Read on Forbes IndiaA multi-year alliance pairing HRV's AI-enabled virtual API platform and market access across 50+ countries with Shodhana's process chemistry and USFDA-aligned GMP infrastructure. Launched with five active development programmes.
Read the announcementAlso in: Indian Pharma Post · AlchemPro
On the Budget's biologics bet and the proposed CDSCO scientific review cadre, and what it would take for the initiative to make India a credible biopharma manufacturing and innovation destination globally.
Read on Forbes IndiaTransparency in pharma is a trust problem before it is a data problem. On what has to change between partners before shared visibility is worth building.
Read the columnOrchestration, not automation, is the shift that matters: coordinating decisions across sourcing, manufacturing and regulatory in real time rather than optimising each of them in isolation.
Read the columnAn exclusive multi-year partnership with Haleos Labs (formerly SMS LifeSciences) covering development, scale-up and GMP manufacturing of orphan, ultra-rare and niche-therapeutic APIs. Five initial programmes, multiple US DMFs filed.
Read the announcementAlso in: Medical Dialogues · Pharmabiz · GeneOnline
Strategic partnership announcement strengthening CDMO capabilities and expanding global market reach through integrated API manufacturing.
Read Full StoryExamining how digital intelligence and AI-driven systems are building resilience into pharmaceutical supply chains to ensure continuity.
Read AnalysisLatest insights from CPHI Frankfurt 2025 covering pharmaceutical innovation, global market dynamics, and the future of API manufacturing.
Watch InterviewHow pharmaceutical companies can leverage digital transformation to create resilient, adaptive supply chains that respond to market disruptions.
Read StrategyA 100 per cent tariff may not hit India's generic exports directly, but it signals that the US wants pharmaceutical manufacturing closer to home. On preparing for policy shifts rather than reacting to them.
Read the analysisExploring how artificial intelligence is transforming demand forecasting, supply chain optimization, and inventory management in pharmaceuticals.
Read ArticleGLP-1 analogues such as Semaglutide are India's next chance to dominate complex generics -- on what deepening capability, rather than reverse engineering, would actually take.
Explore OpportunityOn how technology-driven, asset-light models improve cost efficiency, scalability and regulatory agility, in conversation with Elets News Network.
Read the interviewIndustry Innovation
Traditional pharmaceutical manufacturing demands massive upfront capital and infrastructure. But what if we could build a global pharma company without owning a single factory? This is the story of how HRV Pharma is pioneering India's first integrated virtual API company, proving that smart partnerships and compliance-first thinking can unlock markets traditional models can't reach.
Read Full Insight →Leadership Perspective
Playing badminton at an international level taught me as much about business strategy as any MBA program. Every match required preparation, pattern recognition, and mid-game adaptation. These same principles guide how I build companies and make decisions under uncertainty—recognizing opportunities, adapting to competitive threats, and maintaining focus under pressure.
Explore More →Industry Analysis
Despite advances in drug discovery and manufacturing, emerging markets continue to face significant barriers to pharmaceutical access. The problem isn't just cost—it's regulatory complexity, distribution inefficiencies, and business models optimized for large, established markets. Understanding these barriers and innovating solutions is critical to democratizing healthcare globally.
Read Analysis →Leadership Philosophy
My philosophy is building businesses that create sustainable value by prioritizing long-term partnerships, compliance, and resilient systems over rapid scaling and quick exits. This approach ensures the pharmaceutical supply chain remains stable and trustworthy for decades, which is critical when dealing with essential, life-saving APIs and drugs that impact millions.
Read More →Strategic Vision
The future of pharmaceutical manufacturing lies in digital-first systems that enable real-time visibility, predictive analytics, and adaptive supply chains. By embedding AI and data science into every operational layer, companies can anticipate disruptions, optimize resource allocation, and deliver medicines to patients faster.
Explore Vision →